| 程 蒙,崔彦芝,李 颖.唑来膦酸在乳腺癌辅助治疗中的临床应用及机制探讨[J].中国肿瘤,2014,23(5):394-398. |
| 唑来膦酸在乳腺癌辅助治疗中的临床应用及机制探讨 |
| Zoledronic Acid in the Adjuvant Therapy for Breast Cancer and Its Potential Mechanism |
| 投稿时间：2014-01-07 |
| DOI：10.11735/j.issn.1004-0242.2014.05.A010 |
|
 |
| 中文关键词: 唑来膦酸 乳腺癌 辅助治疗 机制 |
| 英文关键词:zoledronic acid breast cancer adjuvant treatment mechanisms |
| 基金项目: |
|
| 摘要点击次数: 2055 |
| 全文下载次数: 894 |
| 中文摘要: |
| 摘 要：第三代双膦酸盐类药物唑来膦酸是治疗乳腺癌骨转移公认的标准药物之一，但其在乳腺癌辅助治疗中的应用地位尚存在争议。目前临床研究结果表明，唑来膦酸辅助治疗不仅可以提高骨密度，而且可以降低乳腺癌的复发和转移。在低雌激素水平环境下，唑来膦酸可使早期乳腺癌患者得到生存获益，而且早期应用的益处优于延迟应用。唑来膦酸通过抑制肿瘤转移过程中的多条途径而发挥抗肿瘤作用。但唑来膦酸的最佳剂量、治疗周期及持续时间尚有待进一步的研究予以确认。 |
| 英文摘要: |
| Abstract：The third-generation bisphosphonates（BPs) zoledronic acid（ZOL） is one of the accepted standard drugs to treat breast cancer with bone metastasis . However，its application status in the adjuvant treatment for breast cancer is still controversial. Current clinical research results show that ZOL not only can improve bone mineral density (BMD)，but also reduce the recurrence and metastasis of breast cancer. At low level estrogen environment，ZOL may improve survival in patients with early breast cancer. Early application is superior to delay application. ZOL plays anti-tumor effect on multiple procedures inhibit to tumor metastasis. However，the optimal dose，treatment cycles and the duration maintain remain to be confirmed by further studies. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|